Organ damage mitigation with the Baskent Sickle Cell Medical Care Development Program (BASCARE).

about

Organ damage mitigation with the Baskent Sickle Cell Medical Care Development Program (BASCARE).

Item

http://www.wikidata.org/entity/Q50117816

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Organ damage mitigation with t ...... Development Program (BASCARE).

@en

Organ damage mitigation with the Baskent Sickle Cell Medical Care Development Program

@nl

type

Item

label

Organ damage mitigation with t ...... Development Program (BASCARE).

@en

Organ damage mitigation with the Baskent Sickle Cell Medical Care Development Program

@nl

prefLabel

Organ damage mitigation with t ...... Development Program (BASCARE).

@en

Organ damage mitigation with the Baskent Sickle Cell Medical Care Development Program

@nl

P1476

Organ damage mitigation with t ...... Development Program (BASCARE).

@en

P2093

Aslı Korur

http://www.w3.org/2001/XMLSchema#string

Can Boga

http://www.w3.org/2001/XMLSchema#string

Cigdem Gereklioglu

http://www.w3.org/2001/XMLSchema#string

Erkan Maytalman

http://www.w3.org/2001/XMLSchema#string

Hakan Ozdogu

http://www.w3.org/2001/XMLSchema#string

Ilknur Kozanoglu

http://www.w3.org/2001/XMLSchema#string

Mahmut Yeral

http://www.w3.org/2001/XMLSchema#string

Mutlu Kasar

http://www.w3.org/2001/XMLSchema#string

Nurhilal Turgut Buyukkurt

http://www.w3.org/2001/XMLSchema#string

Pelin Aytan

http://www.w3.org/2001/XMLSchema#string

P2860

Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis

A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.

Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe.

Pulmonary artery pressure and the acute chest syndrome in homozygous sickle cell disease.

Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan.

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Genetics of transfusion recipient alloimmunization: can clues from susceptibility to autoimmunity pave the way?

Problematic hospital experiences among adult patients with sickle cell disease

MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients

Hematopoietic Stem Cell Transplantation in Adult Sickle Cell Disease: Problems and Solutions.

P304

e9844

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000009844

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29419693

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

5944669

http://www.w3.org/2001/XMLSchema#string